Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Parasuram Melarcode Krishnamoorthy

Interventional Cardiology New York, NY Medical Doctor

NPI 1023356805 CMS profile 1389266

1190 5Th Ave, New York, NY 10029

Open in the dashboard

General payments

$38,430

270 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$47,009 paid to institutions, not to them · program years 2022–2024

Through program year 2025, Parasuram Melarcode Krishnamoorthy of New York, NY is reported in the CMS Open Payments database as having received $38,430 across 270 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $47,009 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,941 39
2024 General $3,325 51
2023 General $3,694 54
2022 General $1,229 39
2021 General $920 27
2020 General $725 23
2019 General $20,595 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Parasuram Melarcode Krishnamoorthy
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Parasuram Melarcode Krishnamoorthy were reported at $7,941. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Parasuram Melarcode Krishnamoorthy Interventional Cardiology median Middle half National median
2019 $20,595 $1,097 $329–$3,048 $163
2020 $725 $473 $161–$1,480 $114
2021 $920 $677 $233–$1,827 $132
2022 $1,229 $978 $333–$2,724 $149
2023 $3,694 $1,136 $382–$2,986 $160
2024 $3,325 $1,181 $395–$3,326 $164
2025 $7,941 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $19,610 19 payments
  2. Abbott Laboratories $7,336 15 payments
  3. Edwards Lifesciences Corporation $3,883 28 payments
  4. Boston Scientific Corporation $1,668 21 payments
  5. Abiomed $999 28 payments
  6. Medtronic, Inc. $710 10 payments
  7. Amgen Inc. $702 30 payments
  8. Shockwave Medical, Inc $536 16 payments
  9. AstraZeneca Pharmaceuticals LP $432 22 payments
  10. Siemens Medical Solutions USA, Inc. $424 3 payments
  11. Other $2,130 78 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $18,000 1 payment
  2. Food and Beverage $9,186 247 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $6,000 2 payments
  4. Travel and Lodging $4,593 18 payments
  5. Consulting Fee $375 1 payment
  6. Education $275 1 payment
Products named General payments · program years 2019–2025
  1. CoreValve Evolut Transcatheter Valve Systems $19,610 19 payments
  2. TRICLIP $3,115 2 payments
  3. MITRACLIP $3,021 3 payments
  4. EVOQUE $2,029 9 payments
  5. Impella $542 17 payments
  6. Repatha $494 21 payments
  7. SAPIEN 3 Ultra RESILIA $471 8 payments
  8. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $466 13 payments
  9. CoreValve Evolut Transcatheter Valve Systems $452 4 payments
  10. ACUSON SC2000 Diagnostic Ultrasound System $424 3 payments
  11. Other $4,064 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

290

Median for Interventional Cardiology: 2,236

Drug cost

$67,487

Median for Interventional Cardiology: $380,412

Branded share of claims

36.9%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 30 $32,233
Jardiance Empagliflozin Brand 20 $15,069
Entresto Sacubitril/Valsartan Brand 15 $12,459
Brilinta Ticagrelor Brand 12 $5,809
Atorvastatin Calcium Generic 42 $568
Metoprolol Succinate Generic 33 $470
Torsemide Generic 17 $216
Pantoprazole Sodium Generic 23 $205
Carvedilol Generic 23 $125
Clopidogrel Clopidogrel Bisulfate Brand 30 $120

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$193,726

Medicare's payments for the services billed

Medicare patients

2,006

Average age 76

Services billed

5,096

887 women, 1,119 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 70%
Heart failure 56%
Arthritis 54%
Diabetes 52%
Atrial fibrillation 50%
Chronic kidney disease 44%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $127
$127 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $58
$58 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $42
$42 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $40
$40 — —
ELIQUIS
  • PFIZER INC. $28
$28 30 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

270 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record